Amneal Pharmaceuticals price target raised to $9 from $7 at Truist

Truist raised the firm’s price target on Amneal Pharmaceuticals to $9 from $7 and keeps a Buy rating on the shares. The analyst says the company’s Q1 “was a goldilocks quarter” with all three of the company’s segments posting double-digit growth. While the shares were initially down today as investors digested Amneal’s opioid settlement, this does not sway Truist’s view on the growth upside potential across the business, the analyst tells investors in a research note. The firm still sees upside to Amneal’s just-reaffirmed guidance and appreciates the long-term optionality from new product launches and compounded growth on-top of its Parkinson’s franchise.